Topics

Tumor-Busting: Cancer-Mimicking Peptide Immunotherapy

Cancer Immunotherapy Intercellular Communication & Diseases Immunogenic Cell Death Cell Programmed Death

Cancer-mimicking peptide immunotherapy uses altered peptides, mimotopes, or selected peptide ligands to provoke immunity that cross-recognizes a tumor antigen. Native tumor peptides may bind MHC weakly, stimulate low-affinity T cells, or be constrained by self-tolerance. A carefully modified sequence can improve MHC binding or T-cell receptor engagement while preserving recognition of the natural tumor epitope. Phage display and computational or structural approaches can identify mimics of proteins, carbohydrates, or conformational tumor antigens. The concept offers a defined and manufacturable vaccine component, but improvement against the modified peptide is meaningful only when induced antibodies or T cells attack naturally processed antigen on real tumor cells This strategy emerged from attempts to break weak tumor-antigen tolerance without abandoning the specificity that makes peptide vaccination attractive[1][2][3].

Peptide vaccines are taken up by antigen-presenting cells or bind appropriate MHC molecules, then activate specific CD8 or CD4 T cells with costimulation and inflammatory support. Anchor substitutions can stabilize peptide–MHC, whereas TCR-contact substitutions can change clonal recruitment. A dominant tumor-specific TCR can guide optimization toward ligands that expand useful clones. Mimotopes selected by phage display may reproduce an antigenic surface without sharing its linear sequence, enabling antibody or T-cell responses against difficult targets. Excess modification can redirect immunity exclusively toward the vaccine sequence, produce unpredictable cross-reactivity, or favor clones that bind strongly in vitro but fail to recognize physiological antigen density The best modified ligand can recruit a broader or higher-quality repertoire, but an overly dominant clone may still permit heterogeneous tumor escape[1][2][3].

Applications include therapeutic vaccines, dendritic-cell loading, peptide–nanoparticle delivery, and combinations with checkpoint blockade. Multiple peptides can cover tumor heterogeneity and HLA diversity, while personalized neoantigens reduce central tolerance. Adjuvant choice, lymph-node delivery, helper epitopes, and dosing schedule determine whether vaccination generates memory or transient expansion. Peptide-based materials can assemble into depots or nanostructures, increasing uptake but changing persistence and innate signaling. Safety assessment must screen normal-protein cross-reactivity, especially when affinity enhancement recruits T cells outside the natural repertoire. Tumor biopsy should confirm that the target peptide is processed and presented Patient HLA type limits universality, and peptide processing can differ between vaccine-loaded dendritic cells and malignant tissue in vivo[1][3].

Future development should combine immunopeptidomics, structural modeling, and functional validation with primary human cells. Candidate ranking must include MHC binding, complex stability, TCR breadth, natural tumor recognition, and absence of normal-tissue killing. Randomized trials should separate the contribution of peptide modification from adjuvant and checkpoint therapy. Monitoring should track vaccine-specific clones into tumor and test their response to unmodified antigen. Mimotopes can overcome weak native immunogenicity, but they succeed only by faithfully redirecting immunity back to cancer; a strong response against an artificial peptide without native cross-recognition is a manufacturing accomplishment, not an antitumor mechanism The most informative studies will compare recognition of peptide-pulsed cells, naturally expressing tumor cells, and matched normal tissues at physiologic antigen levels. Durability will require memory clones that recognize multiple native tumor variants, because selective pressure against one peptide–MHC complex can still produce antigen-processing or HLA escape[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L073 Anti-Hepatitis C Virus Compound Library
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 394 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Disease Focused Libraries

83
HY-L105 Peptide Library
Peptides are a group of biologically active substances that are involved in various cellular functions of organisms. Peptides are often used in functional analysis, vaccine research and especially in the field of drug research and development. At present, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain. MedChemExpress (MCE) offers a comprehensive collection of 2,647 peptides, including bioactive peptides, amino acid derivatives, and blocking peptides. MCE Peptide Library can be used for peptide library screening, peptide drug discovery, vaccine development, target verification, structural activity research, etc.

Structure Classified Libraries

83
HY-L172 Immunopotentiator Compound Library
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 150 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

Compound Characteristic Classified Libraries

83
HY-L937 Unnatural Amino Acids Fragment library
Unnatural amino acids (UAAs), also referred to as non-canonical amino acids (ncAAs) or non-proteinogenic amino acids, are a class of amino acids that are distinct from the 20 standard natural amino acids. They can be obtained through chemical synthesis, biosynthesis, and other approaches, with structural diversity far exceeding that of natural amino acids. UAAs are mainly including naturally occurring non-canonical amino acids, chemically synthesized amino acids, and biosynthetic amino acids, which provide a molecular basis for protein function design. UAAs exhibit significant value in multiple fields. They can optimize the pharmacokinetic properties of peptide drugs and peptidomimetics, modify enzyme functions and endow them with new biological activities, thereby overcoming the limitations of traditional peptide drugs and expanding the chemical space . Meanwhile, UAAs can serve as molecular probes to analyze protein-protein interactions and investigate the regulatory mechanisms of protein functions. MCE has compiled a UAAs Fragment Library comprising nearly a thousand unnatural amino acid fragments with extensive coverage of chemical space and enhanced structural diversity. This compound library can be widely applied in peptide synthesis, drug design, and protein engineering.

Functional Fragment Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-N0822 Shikonin
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
Exosomes   Chloride Channel   Pyruvate Kinase   NF-κB   TNF Receptor   HIV   AIM2  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
74
HY-A0003 Lenalidomide
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
Molecular Glues   Ligands for E3 Ligase   IKZF Family   Casein Kinase   Apoptosis   Pyroptosis   MDM-2/p53   TNF Receptor  
Inflammation or Immune System Disease   Renal Disease   Chronic Lymphocytic Leukemia   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Myelodysplastic Syndrome   Liver Failure  
63
HY-123606 GSK484
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8+ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.
Protein Arginine Deiminase   MHC  
Digestive System Disease   Colitis   Sickle Cell Disease   Cardiomyopathy   Rheumatoid Arthritis  
57
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
35
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-104026B L-Kynurenine sulfate
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype.
Endogenous Metabolite   Aryl Hydrocarbon Receptor  
Inflammation or Immune System Disease  
31
HY-P9970 Infliximab
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Species: Human

TNF Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Lung Cancer   Breast Cancer  
30
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P1489A OVA Peptide(257-264) TFA
OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P1489 OVA Peptide(257-264)
OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
25
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-P9908 Adalimumab
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Species: Human

TNF Receptor   Bacterial  
Cancer   Autoimmune Disease  
20
HY-108847 Etanercept
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
TNF Receptor   Bacterial  
Cancer   Rheumatoid Arthritis  
16
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-113962 7α,25-Dihydroxycholesterol
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.
EBI2/GPR183   Endogenous Metabolite  
Inflammation or Immune System Disease  
5
HY-123941 FKBP12 PROTAC dTAG-7
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRASG12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research.
PROTACs   FKBP   Epigenetic Reader Domain   HDAC   Histone Methyltransferase   c-Myc   Polo-like Kinase (PLK)   Ras   MHC  
Leukemia/Lymphoma/Myeloma  
4
HY-116330 Hyperforin
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.
Calcium Channel   TRP Channel  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
3
HY-N4087 Platycodin D2
Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology.
Mitophagy   Autophagy   Ferroptosis   Interleukin Related   IFNAR   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease  
3
HY-P1876B NLS (PKKKRKV) (hydrochloride)
NLS (PKKKRKV) hydrochloride is the hydrochloride form of NLS (PKKKRKV) (HY-P1876). NLS (PKKKRKV) is a nuclear localization signal (NLS) derived from the simian virus 40 large tumor antigen (SV40 large T antigen), that mediates binding of the karyophilic protein to importin α. NLS (PKKKRKV) can function as a method to enhance nuclear entry in the field of gene transfer research.
DNA/RNA Synthesis  
Cancer  
3
HY-116330A Hyperforin dicyclohexylammonium salt
Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.
TRP Channel   Calcium Channel  
Cancer   Neurological, Eye or Ear Disease  
3
HY-109520 Glatiramer acetate
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
MHC  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
2
HY-P99051 Tinurilimab
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-N1480R (-)-Fucose (Standard)
(-)-Fucose (Standard) is the analytical standard of (-)-Fucose. This product is intended for research and analytical applications. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. (-)-Fucose is orally active, inhibits CL11-induced inflammatory response in kidney and tumor growth.
Reference Standards   Endogenous Metabolite   Parasite  
Cancer   Infection   Metabolic or Endocrine Disease  
1
HY-P99276 Abagovomab
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a mouse monoclonal anti-idiotypic antibody that targets the tumor-associated antigen CA-125 (binding affinity: 0.5 nM). Produced by mouse hybridoma cells, Abagovomab mimics human TAA, CA-125. Abagovomab also induces humoral and cellular immune responses against ovarian cancer (oc).

Species: Human

Transmembrane Glycoprotein  
Cancer  
1
HY-N0910 Notoginsenoside Ft1
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8+ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance.
PI3K   mTOR   Akt   Apoptosis   p38 MAPK   ERK   Transmembrane Glycoprotein   Glutathione Reductase (GR)   Estrogen Receptor/ERR   Calcium Channel   Ferroptosis   G protein-coupled Bile Acid Receptor 1   FXR  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
1
HY-19480 Ulodesine
Ulodesine (BCX4208) is a purine nucleoside phosphorylase (PNP) inhibitor, with an IC50 of 2.293 nM against human PNP, and low nanomolar IC50 values against mouse, rat and monkey PNP. Ulodesine blocks the production of uric acid precursors, reduces serum uric acid levels, clears accumulated uric acid in the blood, and elevates the levels of purine nucleosides including guanosine. Ulodesine reduces the counts of total lymphocytes, T lymphocytes and lymphocyte subsets, inhibits the proliferation of cancer cells and activated lymphocytes, and enhances vaccine immune responses. Ulodesine can be used in research related to hyperuricemia and gout.
Phosphatase  
Inflammation or Immune System Disease   Hyperuricemia   Gout  
1
HY-P99742 Mitazalimab
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

Species: Human

TNF Receptor  
Cancer  
1
HY-126855 Cholic acid 7-sulfate
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
G protein-coupled Bile Acid Receptor 1   MHC  
Glucose Metabolism   Obesity  
1
HY-P99394 Talquetamab
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

Species: Human

CD3  
Cancer  
1
HY-P99592 Solitomab
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.

Species: Human

CD3  
Ovarian Cancer  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P990007 Tulisokibart
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.

Species: Human

TNF Receptor  
Digestive System Inflammation   Crohn's Disease   Ulcerative Colitis  
1
HY-P76687 UBASH3A Protein, Human (His)
UBASH3A interferes with CBL-mediated downregulation and degradation of receptor-type tyrosine kinases and promotes the accumulation of activating receptors such as T cell receptors, EGFR and PDGFRB on the cell surface. It exhibits minimal protein tyrosine phosphatase activity and may act as a dominant negative regulator of UBASH3B-dependent dephosphorylation. UBASH3A Protein, Human (His) is the recombinant human-derived UBASH3A protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

Ubiquitin Related Proteins Ubiquitin Enzymes

1
HY-P81703 TIM3 Antibody (YA1448)
TIM3 Antibody (YA1448) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to TIM3.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

1
HY-P3315 Onilcamotide
Onilcamotide (RV001) is a C-terminal peptide of RhoC protein. Onilcamotide is a cancer vaccine and has potential immunomodulating and antineoplastic activities.
Others  
Inflammation or Immune System Disease  
/
HY-P10740 CBP-1018
CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer.
Peptide-Drug Conjugates (PDCs)   PSMA   Folate Receptor (FR)  
Castration-Resistant Prostate Cancer  
/
HY-156087G Cholicamideβ (GMP)
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis.
Apoptosis   Necroptosis  
/
HY-P11422 CKS9
CKS9 is an M cell-targeting polypeptide with the amino acid sequence CKSTHPLSC, forming a 9-mer peptide via cyclization through a disulfide bond between the two cysteine residues. CKS9 is obtained through phage display technology screening and has high affinity for M cells. CKS9 can promote chitosan nanoparticles to cross M cells and enter the follicle-associated epithelium (FAE) of intestinal Peyer's patches (PP). CKS9 can be used in studies related to swine dysentery and oral delivery.
Others  
Infection  
/
HY-174359C Alkyne-PEG5000-NH2
Alkyne-PEG5000-NH2 is an alkyne-functionalized bifunctional PEG derivative that can be used to modify proteins, peptides, and other materials. The alkyne group reacts with azides in aqueous solution in a copper-catalyzed manner. PEGylation can increase solubility and stability and reduce the immunogenicity of peptides and proteins.
Biochemical Assay Reagents  
/
HY-N13723 Methyl lucidenate D
Methyl lucidenate D is a selective inhibitor of Epstein-Barr virus early antigen (EBV-EA) activation with an IC50 of 290 mol ratio/32 pmol TPA. Methyl lucidenate D exerts potential anti-tumor promoting activity by inhibiting TPA-induced EBV-EA activation and maintains major Raji cell survival (70%) at effective concentrations. Methyl lucidenate D can be used in the field of cancer chemoprevention.
EBV  
Cancer  
/
HY-P991820 Anti-Mouse CD45 Antibody (I3/2.3)
Anti-Mouse CD45 Antibody (I3/2.3) reacts with the mouse CD45. CD45 plays a key role in T-cell receptor (TCR) and B-cell receptor (BCR) signal transduction. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

Species: Mouse

Phosphatase  
Inflammation or Immune System Disease  
/
HY-N13338 Avicin D
Avicin D is a plant triterpenoid. Avicin D induces Autophagy by activation of AMPK. Avicin D inhibits mTOR and S6 kinase activity. Avicin D selectively induces Apoptosis and downregulates p-STAT-3, bcl-2, and Survivin. Avicin D has properties of being a selective Glucocorticoid receptor modulator. Avicin D inhibits NF-κB activation. Avicin D shows anti-tumor effects against cutaneous T-cell lymphomas.
AMPK   Autophagy   mTOR   Ribosomal S6 Kinase (RSK)   Apoptosis   STAT   Bcl-2 Family   Survivin   Glucocorticoid Receptor   NF-κB  
Leukemia/Lymphoma/Myeloma  
/
HY-W1049092H mPEG3400-N3
mPEG3400-N3 can be used to modify proteins, peptides, and other materials. The azide group can react with alkynes in aqueous solution catalyzed by copper. It can also be easily reduced to an amine group. PEGylation can increase solubility and stability and reduce the immunogenicity of peptides and proteins. mPEG3400-N3 can also inhibit the nonspecific binding of charged molecules to the modified surface.
Biochemical Assay Reagents  
/
HY-W1052262D Silane-PEG1000-Mal
Silane-PEG1000-Mal is a PEG derivative that can be used to modify proteins, peptides and other materials. Silane-PEG1000-Mal can be used for peptide modification and drug delivery.
Biochemical Assay Reagents  
/
HY-D2760A BP Fluor 488 acid triTEA
BP Fluor 488 acid triTEA is a powerful labeling dye. It will react with the amine group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications.
Fluorescent Dye  
/
HY-P991510 CDX-1140
CDX-1140 is a fully human IgG monoclonal antibody and CD40 agonist, with a Kd value of 0.01 nM against human targets. The epitope of CDX-1140 locates at CD40 CRD1 and avoids the CD40L binding site. It activates DCs and B cells, drives NF-κB reporter gene activation, exhibits agonist activity independent of FcR cross-linking, and shows a synergistic effect with recombinant CD40L. CDX-1140 does not induce systemic cytokine release, exerts direct and immune-mediated anti-tumor activity in tumor xenografts, and has favorable safety profiles. When used as a local vaccine adjuvant in combination with 6MHP+mBRAF+poly-ICLC, CDX-1140 increases the number of DC-LAMP+ DCs and induces Th1 CD4+ responses in high-risk melanoma. CDX-1140 can be used in studies related to B-cell lymphoma, bladder cancer and high-risk melanoma.

Species: Human

TNF Receptor  
Bladder Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-D1790 Vari Fluor 640 SE
Vari Fluor 640 SE (VF 640 SE) is a dye marker of the Vari Fluor SE series (Ex/Em=648 nm/664 nm). The Vari Fluor SE series of dyes are a class of fluorescent dyes containing NHS ester groups used to label free amines (-NHX) on antibodies, proteins, peptides, amine-modified oligonucleotides and other biomolecules.
Fluorescent Dye  
/
HY-W777169 Bexarotene-13C4
Bexarotene-13C4 (LGD1069-13C4) is the 13C-labeled Bexarotene (HY-14171). Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM). Bexarotene can be used for the research of cutaneous T-cell lymphoma.
Isotope-Labeled Compounds   Autophagy   RAR/RXR  
Cancer  
/
HY-W027544S MCA-d3
MCA-d3 (7-Methoxycoumarin-4-acetic acid3) is the deuterium labeled MCA (HY-W027544). MCA is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities.
Isotope-Labeled Compounds   Fluorescent Dye  
/
HY-P1822A BDC2.5 mimotope 1040-31 TFA
BDC2.5 mimotope 1040-31 TFA, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg+ T cells.
Transmembrane Glycoprotein  
Metabolic or Endocrine Disease  
/
HY-N12537A (2R,3S)-PD-1/PD-L1-IN-38
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8+T cells and inhibits the signal transduction of PD-1/PD-L1.
Aryl Hydrocarbon Receptor   PD-1/PD-L1  
Cancer  
/
HY-W714047 Valerianol
Valerianol is a sesquiterpene alcohol with anticancer, antibacterial, and antiviral activities. Valerianol selectively inhibits TPA (HY-18739)-induced Epstein-Barr virus early antigen (EBV-EA) activation (IC50=300 μM). Valerianol inhibits tumor promoter-mediated EBV-EA activation and also inhibits pathogenic bacteria such as Staphylococcus aureus.
EBV   Bacterial  
Plant Infection  
/
HY-149773S HPK1-IN-40-d2
HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC50 of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity.
MAP4K  
Cancer   Inflammation or Immune System Disease  
/
HY-W062109S Olopatadine-d6
Olopatadine-d6 is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Isotope-Labeled Compounds   Histamine Receptor   CXCR  
Inflammation or Immune System Disease  
/
HY-P99726 Maslimomab
Maslimomab is a murine monoclonal antibody targeting T-cell receptor. Maslimomab is an immunosuppressive agent.

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P1700 BCMA72-80
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
TNF Receptor  
Cancer  
/
HY-P10739C WYRGRLC
WYRGRLC is a type II collagen-targeting peptide. WYRGRLC specifically binds to type II collagen α1 in articular cartilage in a sequence-dependent manner. WYRGRLC inhibits the binding of WYRGRL-displaying phage (C1-3) to articular cartilage in a sequence-specific manner. WYRGRLC can act as a retention enhancer to improve the cartilage-targeting ability of polymeric nanoparticles and liposomal nanoplatforms, facilitating the delivery of Rapamycin (HY-10219) to chondrocytes. WYRGRLC can be used in studies related to osteoarthritis.
Collagen   Apoptosis  
Inflammation or Immune System Disease   Osteoarthritis  
/
HY-P10686 CH401 peptide
CH401 peptide is a HER2-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate.
EGFR  
Cancer  
/
HY-126675G AS2863619 (GMP)
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4+ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.
CDK   Apoptosis   TGF-beta/Smad   STAT  
Digestive System Disease   Periodontal Disease  
/
HY-B0426AS2 Olopatadine-d6 hydrochloride
Olopatadine-d6 (ALO4943A-d6; KW4679-d6) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Isotope-Labeled Compounds   Histamine Receptor   CXCR  
Inflammation or Immune System Disease  
/
HY-W998644 PB LC acid
PB LC acid is a blue-fluorescent dye that is reactive with primary amines on biomolecules such as peptides, proteins, modified nucleotides and biopolymers (Ex/Em = 410/455 nm).
Fluorescent Dye  
/
HY-W1052262B Silane-PEG5000-Mal
Silane-PEG5000-Mal is a PEG derivative that can be used to modify proteins, peptides and other materials. Silane-PEG5000-Mal can be used for peptide modification and drug delivery.
Biochemical Assay Reagents  
/
HY-D1611 BODIPY FL-C5 NHS Ester
BODIPY FL-C5 NHS Ester is a green-fluorescent dye that is reactive with primary amines on biomolecules such as peptides, proteins, modified nucleotides and biopolymers.
Fluorescent Dye  
/
HY-P10295 p53 (232-240)
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system.
MDM-2/p53  
/
HY-16658BG Z-VAD-FMK (GMP)
Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.
Caspase   Apoptosis  
Cancer  
/
HY-B0426AR Olopatadine hydrochloride (Standard)
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Reference Standards   Histamine Receptor   CXCR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W1049092E mPEG1000-N3
mPEG1000-N3 can be used to modify proteins, peptides, and other materials. The azide group can react with alkynes in aqueous solution catalyzed by copper. It can also be easily reduced to an amine group. PEGylation can increase solubility and stability and reduce the immunogenicity of peptides and proteins. mPEG1000-N3 can also inhibit the nonspecific binding of charged molecules to the modified surface.
Biochemical Assay Reagents  
/
HY-116330AR Hyperforin dicyclohexylammonium salt (Standard)
Hyperforin dicyclohexylammonium salt (Standard) is the analytical standard of Hyperforin dicyclohexylammonium salt. This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model.
Reference Standards   TRP Channel   Calcium Channel  
Neurological, Eye or Ear Disease  
/
HY-P1910 BDC2.5 mimotope 1040-51
BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice.
Others  
Metabolic or Endocrine Disease  
/
HY-P5292 HYNIC-iPSMA
HYNIC-iPSMA is a PSMA-targeted ligand for tumor molecular imaging, with a Ki value of 3.11 nM. HYNIC-iPSMA consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC acts as a chelating moiety to link radionuclides to the targeting molecule; iPSMA is a specific inhibitor that targets Prostate-Specific Membrane Antigen (PSMA). 68Ga-labeled iPSMA is used for prostate cancer detection via PET imaging, while the further developed 99mTc-EDDA/HYNIC-iPSMA TFA exhibits excellent specificity and sensitivity. HYNIC-iPSMA can be used for the synthesis and research of radionuclide-conjugated drugs (RDC).
Radionuclide-Drug Conjugates (RDCs)   PSMA  
Prostate Cancer  
/
HY-N17638 7-Oxomogroside V
7-Oxomogroside V is a cucurbitane-type glycoside isolated from the fruits of Siraitia grosvenorii. 7-Oxomogroside V inhibits the activation of Epstein-Barr virus early antigen (EBV-EA) induced by TPA (HY-18739). 7-Oxomogroside V also exerts weak inhibitory effects on the activation of the nitric oxide donor NOR 1. 7-Oxomogroside V is applicable to tumor-related research.
EBV   NO Synthase  
Cancer   Viral Infection  
/
HY-W1052262 Silane-PEG2000-Mal
Silane-PEG2000-Mal is a PEG derivative that can be used to modify proteins, peptides and other materials. Silane-PEG2000-Mal can be used for peptide modification and drug delivery.
Biochemical Assay Reagents  
/
HY-P10417 RTDLDSLRTYTL
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development.
Integrin   IFNAR  
Cancer  
/
HY-P10315 [Gln144]-PLP (139-151)
[Gln144]-PLP (139-151) is an experimental antigen used to study T cells respond to both autoantigens and cross-reactive non-autoantigens. [Gln144]-PLP (139-151) activates T cells by binding to T-cell Receptor (TCR), which triggers an immune response. [Gln144]-PLP (139-151) can be used to study the regulation of autoimmune diseases.
Transmembrane Glycoprotein  
/
HY-P3444A CD31 TFA
CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation-.
SHP2   Bacterial  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P10701 Q11 peptide
Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P11059 MC38 SLP Reps1
MC38 SLP Reps1 is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines.
Others  
/
HY-14171S2 Bexarotene-13C6
Bexarotene-13C6 (LGD1069-13C6) is 13C labeled Bexarotene. Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM). Bexarotene can be used for the research of cutaneous T-cell lymphoma.
Isotope-Labeled Compounds   Autophagy   RAR/RXR  
Cancer  
/
HY-N0475R Triptophenolide (Standard)
Triptophenolide (Standard) (Hypolide) is the analytical standard of Triptophenolide (HY-N0475). This product is intended for research and analytical applications. Triptophenolide is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC50 of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer.
Reference Standards   Androgen Receptor   Pyroptosis   Caspase   Bcl-2 Family   Apoptosis  
Prostate Cancer   Autoimmune Disease   Arthritis   Luminal Breast Cancer   Triple-Negative Breast Cancer  
/
HY-D2858A 8-arm-PEG20000-FITC
8-arm-PEG20000-FITC is a fluorescent dye composed of FITC (HY-66019) and eight-arm polyethylene glycol (8-Arm PEG). 8-arm-PEG-FITC can be used to modify proteins, peptides and other materials with active groups (Ex/Em=488/525 nm).
Fluorescent Dye  
/
HY-D2772 5-TAMRA Cadaverine
5-TAMRA cadaverine can used to modify carboxylic acid group in the presence of activators (e.g. EDC, or DCC) or activated esters (e.g. NHS esters) through a stable amide bond. It also can be reversibly coupled to aldehydes and ketones to form a Schiff base – which can be reduced to a generate stable amine derivative by sodium borohydride (NaBH4) or sodium cyanoborohydride (NaCNH3). Although the mixed isomers of 5(6)-TAMRA cadaverine is a preferred, routinely used orange-fluorescent dye for staining proteins, it is rearly used for labeling peptides and nucleotides. Purification of 5(6)-TAMRA labeled peptide and nucleotides might be troublesome due to significant signal broadening in HPLC purification. Peptides and nucleotides labeled with a single isomer TAMRA usually give better resolution in HPLC purification that is often required in the conjugation processes.
Biochemical Assay Reagents  
/
HY-D2760 BP Fluor 488 acid
BP Fluor 488 acid is a powerful labeling dye. It will react with the amine group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications.
Fluorescent Dye  
/
HY-104026BS L-Kynurenine-13C10 sulfate
L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype.
Aryl Hydrocarbon Receptor   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-B0426AS Olopatadine-d3 hydrochloride
Olopatadine-d3 hydrochloride (ALO4943A-d3) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4+ and CD8+ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis.
Isotope-Labeled Compounds   Histamine Receptor   CXCR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N12978 Benzyl β-gentiobioside
Benzyl β-gentiobioside is a phenyl alcohol glycoside found in peach kernels (Prunus persica seeds). Benzyl β-gentiobioside has anti-tumor promoting activity by inhibiting TPA (12-O-tetradecanoylphorbol 13-acetate, a tumor promoter)-induced Epstein-Barr virus early antigen (EBV-EA) activation.
Others  
Cancer  
/
HY-152003S Ganglioside GM2-d3 ammonium
Ganglioside GM2-d3 (ammonium) is the deuterium labeled Ganglioside GM2 (HY-148385). Ganglioside GM2 is a human tumor antigen predominantly found in human tumor cells and fetal brain tissue. As a sialylated glycosphingolipid, Ganglioside GM2 is involved in processes such as cell signaling, adhesion, and motility. Ganglioside GM2 abnormal expression and accumulation are associated with tumors and neurodegenerative disorders. Ganglioside GM2 promotes tumor cell migration and invasion by directly binding to the integrin β1 receptor, activating the FAK/Src/Erk-MAPK signaling pathway, and inducing actin cytoskeleton remodeling.
Isotope-Labeled Compounds  
/
HY-144002 RIBI-529
RIBI-529 (RC-529) is a fully synthetic, low-toxicity TLR4 agonist vaccine adjuvant. RIBI-529 upregulates cell surface co-stimulatory molecules, receptors, cytokines and chemokines, and activates the innate immune system. RIBI-529 enhances short-term CD4+ T cell clonal expansion, division, and ex vivo survival under growth factor withdrawal conditions. RIBI-529 enhances humoral and cell-mediated adaptive immune responses, induces non-specific resistance against viral and bacterial pathogens, and skews responses toward a Th1 type, accompanied by Th2 responses.
Toll-like Receptor (TLR)   Interleukin Related  
Inflammation or Immune System Disease  
/
HY-P0287A QL9 TFA
QL9 (QLSPFPFDL) TFA is a high-affinity alloantigen for the 2C T cell receptor (TCR).
Others  
Inflammation or Immune System Disease  
/
HY-P0287 QL9
QL9 (QLSPFPFDL) is a high-affinity alloantigen for the 2C T cell receptor (TCR).
Others  
Inflammation or Immune System Disease  
/
HY-P11060 MC38 SLP Adpgk
MC38 SLP Adpgk (Adpgk peptide) is an H-2 Kb-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice.
MHC  
Colorectal Cancer  
/
HY-P990205 Anti-Mouse/Human KLRG-1 Antibody (2F1)
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatory T-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology.

Species: Human/Mouse

C-type Lectin-like Receptors (CTLRs)  
Inflammation or Immune System Disease  
/
HY-D1056B2 Lipopolysaccharides, from Proteus mirabilis
Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-P4116A pH-Low Insertion Peptide TFA
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-104026CS L-Kynurenine-13C10 sulfate hemihydrate
L-Kynurenine-13C10 (sulfate hemihydrate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate hemihydrate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype.
Aryl Hydrocarbon Receptor   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-148775 PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (60kDa-3.4kDa, LA:GA ratio 75:25) can be used for studies related to bacterial wound infections and glioblastoma.
Biochemical Assay Reagents  
Bacterial Infection   Glioblastoma  
/
HY-W1049092 mPEG2000-N3
mPEG2000-N3 can be used to modify proteins, peptides, and other materials. The azide group can react with alkynes in aqueous solution catalyzed by copper. It can also be easily reduced to an amine group. PEGylation can increase solubility and stability and reduce the immunogenicity of peptides and proteins. mPEG2000-N3 can also inhibit the nonspecific binding of charged molecules to the modified surface.
Biochemical Assay Reagents  
/
HY-D1791 Vari Fluor 750 SE
Vari Fluor 750 SE (VF 750 SE) is a dye marker of the Vari Fluor SE series (Ex/Em=747 nm/770 nm). The Vari Fluor SE series of dyes are a class of fluorescent dyes containing NHS ester groups used to label free amines (-NHX) on antibodies, proteins, peptides, amine-modified oligonucleotides and other biomolecules.
Fluorescent Dye  
/
HY-P5488 BDC2.5 Mimotope 1040-63
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)
Others  
/
HY-W020780D mPEG40000-Mal
mPEG40000-Mal is a thiol-reactive PEG derivative that can be used to selectively modify proteins, peptides, or any other surface with available thiol groups.
Biochemical Assay Reagents  
/
HY-P1822 BDC2.5 mimotope 1040-31
BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg+ T cells.
Transmembrane Glycoprotein  
Metabolic or Endocrine Disease  
/
HY-P3444 CD31
CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation-.
SHP2   Bacterial  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-W1123939C Silane-PEG5000-COOH
Silane-PEG5000-COOH can be used to modify proteins, peptides and other materials with active groups. The carboxyl group (-COOH) can easily form a stable amide bond with the amino group, and can also form an ester bond with the hydroxyl group. Silane-functionalized PEG (Silane-PEG-X) can be used to modify glass, silicon, etc.
Biochemical Assay Reagents  
/
HY-14171S Bexarotene-d4
Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma.
RAR/RXR   Autophagy  
Cancer  
/
HY-P991176 RG-6333
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001).

Species: Human

CD19   CD28  
Cancer  
/
HY-117433S 4-Hydroperoxy Cyclophosphamide-d4
4-Hydroperoxy Cyclophosphamide-d4 is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders.
DNA Alkylator/Crosslinker   Apoptosis   Reactive Oxygen Species (ROS)   Drug Metabolite  
Inflammation or Immune System Disease  
/
HY-P10582A SIYNFEKL TFA
SIYNFEKL TFA is a variant of major MHC class I-restricted epitope SIINFEKL. SIYNFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cell. SIYNFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells.
MHC  
Inflammation or Immune System Disease  
/
HY-D1792 Vari Fluor 555 SE
Vari Fluor 555 SE (VF 555 SE) is a dye marker of the Vari Fluor SE series (Ex/Em=550 nm/561 nm). The Vari Fluor SE series of dyes are a class of fluorescent dyes containing NHS ester groups used to label free amines (-NHX) on antibodies, proteins, peptides, amine-modified oligonucleotides and other biomolecules.
Fluorescent Dye  
/
HY-P99254 Racotumomab
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer.

Species: Human

Others  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P10512 BDC2.5 mimotope
BDC2.5 mimotope is a potent antigen-mimicking peptide that can activate CD4+ T cell populations that have the same antigen recognition properties as BDC2.5 cells. BDC2.5 mimotope can be used to study the prevention or treatment of type 1 diabetes by targeting specific T cell populations.
Others  
Glucose Metabolism  
/
HY-P990757 Ragistomig
Ragistomig can simultaneously target programmed death-ligand 1 (PD-L1) and the 4-1BB receptor. Ragistomig elicits potent anti-tumor T-cell responses without inducing significant toxicity. Ragistomig is applicable for tumor research.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-P991214 Tucotuzumab celmoleukin
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer.

Species: Human

Interleukin Related  
Colorectal Cancer  
/
HY-P11107 RP-832c
RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF).
Apoptosis   TNF Receptor  
Inflammation or Immune System Disease  
/
HY-P10581A SIIVFEKL TFA
SIIVFEKL TFA is a variant of the major MHC class I-restricted epitope SIINFEKL. SIIVFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cells. SIIVFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells.
MHC  
Inflammation or Immune System Disease  
/
HY-P10424 OPBP-1
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P991198 M6903
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers.

Species: Human

Tim3  
Cancer  
/
HY-W046355 Fmoc-D-Dap(Boc)-OH
Fmoc-D-Dap(Boc)-OH is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as DOTA-modified peptides and their metal chelates with cancer diagnostic effects.
Radionuclide-Drug Conjugates (RDCs)   Amino Acid Derivatives  
/
HY-P5292A HYNIC-iPSMA TFA
HYNIC-iPSMA TFA is a PSMA-targeted ligand for tumor molecular imaging, with a Ki value of 3.11 nM. HYNIC-iPSMA TFA consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC serves as a chelating moiety to link radionuclides to the targeting molecule; iPSMA is a specific inhibitor that targets Prostate-Specific Membrane Antigen (PSMA). 68Ga-labeled iPSMA is used for prostate cancer detection via PET imaging, while the further developed 99mTc-EDDA/HYNIC-iPSMA TFA exhibits excellent specificity and sensitivity. HYNIC-iPSMA TFA can be used for the synthesis and research of radionuclide-conjugated drugs (RDC).
Radionuclide-Drug Conjugates (RDCs)   PSMA  
Prostate Cancer  
/
HY-P5533 CRT
CRT, an iron peptide mimic, can bind to apo-transferrin (apo-Tf). CRT can be used to modify nanoparticles, and enhances drug delivery efficiency.
Biochemical Assay Reagents  
Cancer  
/
HY-P991490 ISB2001
ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD38   CD3   TNF Receptor  
Cancer  
/
HY-P5290 HYNIC-PSMA
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research. HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Radionuclide-Drug Conjugates (RDCs)   PSMA  
/
HY-N10534 Lewis X trisaccharide
Lewis X trisaccharide (Lewis X, Lex) is a potent TH2 regulator, antagonizes LPS-induced IL-12 immune expression. Lewis X trisaccharide is a human histo-blood group antigen, plays an key role in cell-cell adhesion, and servers as a tumor marker. Lewis X trisaccharide is highly expressed in the outer membrane of the parasite, can be used for the immunology research of schistosomiasis.

Source: human

Parasite  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P2530 KALA
KALA is an amphiphilic peptide that forms an α-helical structure at physiological pH. KALA modifies a plasmid DNA-encapsulating liposomal membrane and is used as a fusogenic peptide in order to achieve effective liver targeting and transfection of DNA via galactose receptors.
Others  
/
HY-N7691 3,29-O-Dibenzoyloxykarounidiol
3,29-O-Dibenzoyloxykarounidiol (Karounidiol dibenzoate) is a multiflorane-type triterpene benzoate that inhibits Phorbol 12-myristate 13-acetate (TPA) (HY-18739)-induced Epstein-Barr virus early antigen activation and exhibits tumor-promotion inhibitory activity. 3,29-O-Dibenzoyloxykarounidiol is used in cancer-related research.
EBV  
Cancer  
/
HY-W002450 L-Cyclohexylalanine
L-Cyclohexylalanine is an amino acid derivative. L-Cyclohexylalanine modifies an atrial natriuretic peptide, regulates homeostasis of body fluid and blood pressure homeostasis and vasodilation activity.
Drug Derivative  
Blood or Cardio-cerebrovascular Disease  
/
HY-P5287 cRGDfK-thioacetyl ester
cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging.
Integrin  
/
HY-P99605 Cinrebafusp alfa
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research.
EGFR   TNF Receptor  
Cancer  
/
HY-P10709 CREKA peptide
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects.
Collagen  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-134393B 6-Me-ATP trisodium solution (100 mM)
6-Me-ATP (N6-Methyl-ATP) trisodium solution (100 mM) is a N6-modified ATP derivative. 6-Me-ATP trisodium shows excellent binding affinity to GSK3, serving as the phosphate group donor for GSK3β-catalyzed phosphorylation of its substrate peptide.
GSK-3  
/
HY-P11303 PADRE peptide
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.
CD74   MHC  
Cervical Cancer   Glioblastoma  
/
HY-P99328 Tucotuzumab
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Lung Cancer  
/
HY-N0475 Triptophenolide
Triptophenolide (Hypolide) is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC50 of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer.
Androgen Receptor   Pyroptosis   Caspase   Bcl-2 Family   Apoptosis  
Prostate Cancer   Luminal Breast Cancer   Triple-Negative Breast Cancer   Rheumatoid Arthritis  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-P991155 Ramantamig
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma.

Species: Human

CD3   TNF Receptor  
Multiple Myeloma  
/
HY-P0277 Carcinoembryonic antigen peptide 1
Carcinoembryonic antigen peptide 1 (CEA peptide) is a 9-amino acid HLA-A0201-binding cytotoxic T lymphocyte (CTL) epitope peptide derived from carcinoembryonic antigen (CEA). The IC50 of Carcinoembryonic antigen peptide 1 binding to HLA-A0201 is 2 μM. Carcinoembryonic antigen peptide 1 binds to HLA-A0201 to form a peptide-MHC I complex, which is recognized by the T cell receptor (TCR) of CAP1-specific CD8+ CTLs, thereby inducing antigen-specific T cell activation, IFN-γ production, and CTL-mediated lysis of target cells. Carcinoembryonic antigen peptide 1 is used in research on CEA-specific CTL responses and colorectal cancer.
IFNAR   MHC  
Colorectal Cancer  
/
HY-P2506A Gp100 (25-33), mouse TFA
Gp100 (25-33), mouse TFA sequence is found in residues 25 to 33 of the mouse self/tumor antigen glycoprotein (mgp100). Mgp100 is an enzyme involved in pigment synthesis, and the epitope fragment is expressed in both normal melanocytes and melanoma cells.
Others  
Cancer  
/
HY-W006886 Fmoc-(R)-2-(7-octenyl)Ala-OH
Fmoc-(R)-2-(7-octenyl) Ala-OH is an unnatural Fmoc-protected amino acid and modification module. Fmoc-(R)-2-(7-octenyl) Ala-OH serves as a key building block for all-hydrocarbon cross-linking modification of antimicrobial peptides, and facilitates the generation of stapled peptide derivatives. When introduced into specific sites of the parent peptide, Fmoc-(R)-2-(7-octenyl) Ala-OH effectively increases the α-helix content of the peptide chain, thereby significantly enhancing its antimicrobial activity and proteolytic stability. Fmoc-(R)-2-(7-octenyl) Ala-OH is widely used in research on bacterial infections and the development of related antimicrobial agents. Stapled peptide is a specially chemically modified polypeptide. It locks the peptide chain into a stable α-helical structure by introducing a "staple"-like chemical bridge (usually an all-carbon backbone) at specific positions of the peptide chain.
Amino Acid Derivatives  
/
HY-W027544 MCA
MCA (7-Methoxycoumarin-4-acetic acid) is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities.
Fluorescent Dye  
/
HY-P99266 Zanolimumab
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
/
HY-P2506 Gp100 (25-33), mouse
Gp100 (25-33), mouse sequence is found in residues 25 to 33 of the mouse self/tumor antigen glycoprotein (mgp100). Mgp100 is an enzyme involved in pigment synthesis, and the epitope fragment is expressed in both normal melanocytes and melanoma cells.
Others  
Cancer  
/
HY-P4116 pH-Low Insertion Peptide
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors.
Others  
Cancer   Metabolic or Endocrine Disease  
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Inflammation or Immune System Disease  
/
HY-P1827 mTRP-2 (180-188)
mTRP-2 (180-188) is an MHC class I-restricted tumor-associated antigenic peptide derived from mouse tyrosinase-related protein 2 (TRP-2). mTRP-2 (180-188) binds to HLA-A*0201 with an ID50 of 36 nM. mTRP-2 (180-188) can be presented by H-2Kb molecules and activate TRP-2-specific cytotoxic T lymphocytes (CTL). mTRP-2 (180-188) induces immune responses against B16 melanoma by promoting antigen-specific T cell proliferation, cytokine release, and CTL-mediated tumor cell killing. mTRP-2 (180-188) can be used in studies related to melanoma, glioma, and tumor immunology.
Tyrosinase   MHC  
Melanoma  
/
HY-20167A H-Glu(OtBu)-OtBu hydrochloride
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies.
Neurokinin Receptor  
Cancer  
/
HY-P3333 KSPWFTTL
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P3503 Vosoritide
Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research.
FGFR  
/
HY-P1587 IRBP (1-20), human
IRBP (1-20), human contains a major epitope for the H-2b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2b mice.
MHC  
Inflammation or Immune System Disease  
/
HY-P4193 AH1
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8+ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I Ld molecule. AH1 can be used for the research of colorectal carcinoma.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-P99203 Cemiplimab
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P9989 Linvoseltamab
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM).

Species: Human

CD3   TNF Receptor  
Cancer  
/
HY-177434 Precemtabart tocentecan
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC.
Antibody-Drug Conjugates (ADCs)   Transmembrane Glycoprotein   Topoisomerase  
Cancer  
/
HY-N1480 (-)-Fucose
(-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interactions. (-)-Fucose is orally active, inhibits CL11-induced inflammatory response in kidney and tumor growth.
Endogenous Metabolite   Parasite  
Cancer   Parasitic Infection   Glucose Metabolism   SARS-CoV-2 Infection  
/
HY-P5005 VIPhyb
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis.
CMV   PD-1/PD-L1  
Inflammation or Immune System Disease  
/
HY-124004 Acetyl-6-formylpterin
Acetyl-6-formylpterin (Ac-6-FP) is a hapten that stabilizes MR1 on antigen-presenting cells, forming an MR1:A6FP complex that fails to activate MAIT cell TCR, thereby acting as a competitive inhibitor of MAIT cell activation. Acetyl-6-formylpterin exacerbates house dust mite-induced airway hyperresponsiveness and elevates circulating IgE levels. Acetyl-6-formylpterin reduces systemic MAIT cell activity and decreases the frequency of IL-17A+ and IFNγ+ MAIT cells in the spleen. Acetyl-6-formylpterin is useful for the study of allergic asthma.
MHC   Interleukin Related   IFNAR  
Allergic Asthma  
/
HY-P99339 Tebentafusp
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.

Species: Human

Interleukin Related   TNF Receptor  
Cancer  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P991015 Pasritamig
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P9954 Catumaxomab
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers.

Species: Human

CD3  
Gastric Cancer   Ovarian Cancer  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P99392 Teclistamab
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

Species: Human

CD3  
Cancer  
/
HY-P71662 CD8 alpha Protein, Human (HEK293, His)
CD8 alpha Protein is expressed on the surface of cytotoxic T cells. It plays a crucial role in immune responses by binding to major histocompatibility complex class I molecules on target cells, enhancing T cell activation and cytotoxicity. CD8 alpha Protein is also involved in immune regulation and tolerance. Understanding its functions can aid in developing immunotherapies and vaccines. CD8 alpha Protein, Human (HEK293, His) is the recombinant human-derived CD8 alpha protein, expressed by HEK293 , with N-6*His labeled tag.

Species: Human; Source: HEK293

CD Antigens T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CD8a

/
HY-P70482 TIM-3/HAVCR2 Protein, Human (HEK293, His)
T cell immunoglobulin mucin-3 is an inhibitory receptor, and inhibits T cell functions. TIM-3 regulates immune responses in autoimmunity and cancer. TIM-3 has multiple different ligands: galectin 9, phosphatidylserine (PtdSer), CEACAM1 and HMGB1. The TIM-3-ligand axis is critical in the pathogenesis of numerous conditions, including autoimmune diseases, infections, cancers, transplant rejection, and chronic inflammation. TIM-3/HAVCR2 Protein, Human (HEK293, His) is the recombinant human-derived TIM-3/HAVCR2 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

Immune Checkpoint Proteins Inhibitory Checkpoint Molecules TIM-3

/
HY-P78753 CD3 gamma Protein, Human (HEK293, Fc)
CD3 gamma is part of the TCR-CD3 complex on T lymphocytes, promoting TCR-mediated signaling and regulating surface expression. APC-induced TCR activation promotes CD3 gamma as well as CD3D, CD3E, and CD3Z signaling through ITAMs. CD3 gamma Protein, Human (HEK293, Fc) is the recombinant human-derived CD3 gamma protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CD Antigens T Cell CD Proteins NK Cell CD Proteins CD3g

/
HY-P76103A TCPTP Protein, Human (sf9)
TCPTP is a non-receptor tyrosine-specific phosphatase that critically regulates various kinases (INSR, EGFR, JAK, Src) affecting hematopoiesis, inflammation, cell proliferation, and glucose homeostasis. In the immune system, TCPTP regulates T cell receptor signaling and inhibits cytokine pathways (IL2, interferon). TCPTP Protein, Human (sf9) is the recombinant human-derived TCPTP protein, expressed by Sf9 insect cells , with tag free.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Phosphatase

/
HY-P74268 CD8 alpha Protein, Mouse (HEK293, His)
CD8A is an important immune glycoprotein that acts as a coreceptor for class I MHC:peptide complexes, linking T cells to antigens presented by APCs. It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways. CD8 alpha Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD8 alpha protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CD8a

/
HY-P74267 CD8 alpha Protein, Rat (HEK293, Fc)
CD8 alpha is an important immune glycoprotein that serves as a coreceptor for MHC class I:peptide complexes, linking T cells to antigens presented by APCs.It interacts with TCR and MHC class I, recruits LCK kinase, and initiates multiple signaling pathways.CD8 alpha Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD8 alpha protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

CD Antigens T Cell CD Proteins Macrophage CD Proteins Dendritic Cell CD Proteins CD8a

/
HY-P71379 TRAT1 Protein, Human (His)
TRAT1 protein stabilizes the T-cell antigen receptor (TCR)/CD3 complex on T-cell surfaces. As a homodimer linked by disulfide bonds, TRAT1 interacts with CD3Z, enhancing the structural integrity and function of the TCR/CD3 complex. Phosphorylated TRAT1 also engages with PIK3R1, indicating its role in signaling pathways related to T-cell activation and response. TRAT1 Protein, Human (His) is the recombinant human-derived TRAT1 protein, expressed by E. coli , with C-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P71845 CD3 gamma Protein, Cynomolgus (P.pastoris, His)
CD3γ protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When the TCR is activated, CD3D, CD3E, CD3G, and CD3Z transmit TCR-mediated signals and activate downstream pathways. CD3 gamma Protein, Cynomolgus (P.pastoris, His) is the recombinant cynomolgus-derived CD3 gamma protein, expressed by P. pastoris , with N-His labeled tag.

Species: Cynomolgus; Source: P. pastoris

CD Antigens T Cell CD Proteins NK Cell CD Proteins CD3g

/
HY-P704153 TRGC1 Protein, Human (HEK293, His)
TRGC1 Protein, Human (HEK293, His) is the recombinant human-derived TRGC1 protein, expressed by HEK293, with C-His tag.

Species: Human; Source: HEK293

/
HY-P80600 CD3D Antibody (YA539)
CD3D Antibody (YA539) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3D.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82680 Phospho-CD3 zeta (Tyr142) Antibody (YA2425)
Phospho-CD3 zeta (Tyr142) Antibody (YA2425) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CD3 zeta (Tyr142).

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P84962 CD137/4-1BB Antibody (YA4654)
CD137/4-1BB Antibody (YA4654) is a non-conjugated antibody, targeting to CD137/4-1BB.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-P80600A CD3D Antibody (YA539)(PBS only)
CD3D Antibody (YA539) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD3D.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811688 UBASH3B/Sts1 Antibody (YA10159)
UBASH3B/Sts1 Antibody (YA10159) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to UBASH3B/Sts1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81895 CD2 Antibody (YA1640)
CD2 Antibody (YA1640) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81895A CD2 Antibody (YA1640)(PBS only)
CD2 Antibody (YA1640) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82680A Phospho-CD3 zeta (Tyr142) Antibody (YA2425)(PBS only)
Phospho-CD3 zeta (Tyr142) Antibody (YA2425) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CD3 zeta (Tyr142).

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P85086 CD3 zeta Antibody (YA4778)
CD3 zeta Antibody (YA4778) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD3 zeta.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/

Keywords

mimotopes | modified peptides | cancer vaccines | T-cell receptor | phage display | tumor antigens